Ignite Creation Date:
2024-05-06 @ 6:28 PM
Last Modification Date:
2024-10-26 @ 2:48 PM
Study NCT ID:
NCT05673928
Status:
RECRUITING
Last Update Posted:
2024-02-29
First Post:
2022-12-30
Brief Title:
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine T-DM1 in Patients with HER2-positive Metastatic Solid Tumors and Metastases to Brain TUCATEMEB
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Organization Data
Organization:
MD Anderson Cancer Center
Class:
OTHER
Study ID:
2021-0899
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MD Anderson Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Seagen Inc | INDUSTRY |
| Genentech Inc | INDUSTRY |